Lipoprotein(a): New Insights into Mechanisms of Atherogenesis and Thrombosis

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2004 Jun 11

PMID 15188938

Citations 28

Authors

Arjun Deb

Noel M Caplice

Affiliations

Soon will be listed here.

Abstract

Lipoprotein(a) (Lp[a]) continues to be a controversial molecule regarding its role in human vascular disease. Although the physiologic role of this molecule is still unclear, novel discoveries within the last few years have suggested numerous mechanisms whereby Lp(a) may contribute to atherosclerosis and its complications in human subjects. These effects may differentially occur in vascular tissue and circulating blood compartments. A complex interplay between tissue-specific effects is probably more relevant to the pathogenicity of this molecule than one single effect alone. This review briefly describes the structure of Lp(a) in relation to its biochemical function, summarizing the current literature on various pathophysiologic mechanisms of Lp(a)-induced vascular disease and the role of cell and tissue-specific effects in promoting atherogenesis and thrombosis.

Citing Articles

Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease.

Doherty S, Hernandez S, Rikhi R, Mirzai S, De Los Reyes C, McIntosh S Curr Cardiovasc Risk Rep. 2025; 19(1):8.

PMID: 39980866 PMC: 11836235. DOI: 10.1007/s12170-025-00760-1.

Elevated serum lipoprotein(a) levels as a potential risk factor for diabetic retinopathy in type 2 diabetes: a meta-analysis.

Pang Y, Yi C Int Ophthalmol. 2024; 44(1):439.

PMID: 39579229 DOI: 10.1007/s10792-024-03360-x.

Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients.

Cancro F, Bellino M, Silverio A, Di Maio M, Esposito L, Palumbo R Transl Med UniSa. 2024; 26(2):99-110.

PMID: 39385797 PMC: 11460530. DOI: 10.37825/2239-9747.1058.

The levels of serum lipoprotein(a) on clinical outcomes in Chinese hospitalized patients with cardiovascular diseases.

Min T, Yue Y, Fan X, Yang D, Su S, Wan H Eur J Med Res. 2024; 29(1):421.

PMID: 39152471 PMC: 11330145. DOI: 10.1186/s40001-024-01957-7.

Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES.

Wang Z, Yan X, Fang L, Tang J, Zhang J BMC Public Health. 2024; 24(1):1927.

PMID: 39026192 PMC: 11256372. DOI: 10.1186/s12889-024-19443-4.

References

Gosling J, Slaymaker S, Gu L, Tseng S, Zlot C, Young S . MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999; 103(6):773-8. PMC: 408147. DOI: 10.1172/JCI5624. View

Edelstein C, Shapiro S, Klezovitch O, Scanu A . Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology. J Biol Chem. 1999; 274(15):10019-23. DOI: 10.1074/jbc.274.15.10019. View

Gerszten R, Garcia-Zepeda E, Lim Y, Yoshida M, Ding H, Gimbrone Jr M . MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999; 398(6729):718-23. DOI: 10.1038/19546. View

Ganne F, Vasse M, Beaudeux J, Peynet J, Francois A, Paysant J . Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins--consequences for plasmin generation and monocyte adhesion. Thromb Haemost. 1999; 81(4):594-600. View

Hobbs H, White A . Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999; 10(3):225-36. DOI: 10.1097/00041433-199906000-00005. View

Plow E, Ploplis V, Busuttil S, Carmeliet P, Collen D . A role of plasminogen in atherosclerosis and restenosis models in mice. Thromb Haemost. 2000; 82 Suppl 1:4-7. View

Moeslinger T, Friedl R, Volf I, Brunner M, Koller E, Spieckermann P . Inhibition of inducible nitric oxide synthesis by oxidized lipoprotein(a) in a murine macrophage cell line. FEBS Lett. 2000; 478(1-2):95-9. DOI: 10.1016/s0014-5793(00)01825-1. View

Lusis A . Atherosclerosis. Nature. 2000; 407(6801):233-41. PMC: 2826222. DOI: 10.1038/35025203. View

Buechler C, Ullrich H, Ritter M, Lackner K, Barlage S, Friedrich S . Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood. 2001; 97(4):981-6. DOI: 10.1182/blood.v97.4.981. View

10.

Angles-Cano E, De la Pena Diaz A, Loyau S . Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci. 2001; 936:261-75. DOI: 10.1111/j.1749-6632.2001.tb03514.x. View

11.

Klezovitch O, Edelstein C, Scanu A . Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem. 2001; 276(50):46864-9. DOI: 10.1074/jbc.M107943200. View

12.

Caplice N, Panetta C, Peterson T, Kleppe L, Mueske C, Kostner G . Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001; 98(10):2980-7. DOI: 10.1182/blood.v98.10.2980. View

13.

Jarvelainen H, Iruela-Arispe M, Kinsella M, Sandell L, Sage E, Wight T . Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis in vitro. Exp Cell Res. 1992; 203(2):395-401. DOI: 10.1016/0014-4827(92)90013-x. View

14.

Asundi V, Dreher K . Molecular characterization of vascular smooth muscle decorin: deduced core protein structure and regulation of gene expression. Eur J Cell Biol. 1992; 59(2):314-21. View

15.

Haberland M, Fless G, Scanu A, Fogelman A . Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 1992; 267(6):4143-51. View

16.

Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N . Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992; 69(16):1251-4. DOI: 10.1016/0002-9149(92)91215-p. View

17.

Lindhout T, Blezer R, Schoen P, Nordfang O, Reutelingsperger C, Hemker H . Activation of factor X and its regulation by tissue factor pathway inhibitor in small-diameter capillaries lined with human endothelial cells. Blood. 1992; 79(11):2909-16. View

18.

Coleman M, Key T, Wang D, Hermon C, Fentiman I, Allen D . A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis. 1992; 92(2-3):177-85. DOI: 10.1016/0021-9150(92)90276-m. View

19.

Dahlen G, Berg K, GILLNAS T, Ericson C . Lp(a) lipoprotein/pre-beta1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin Genet. 1975; 7(4):334-41. DOI: 10.1111/j.1399-0004.1975.tb00338.x. View

20.

Jarvelainen H, Kinsella M, Wight T, Sandell L . Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem. 1991; 266(34):23274-81. View